☰

John Gordan - Publications

Affiliations: 
2011-2016 Cellular and Molecular Pharmacology University of California, San Francisco, San Francisco, CA 
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Lauer SM, Omar MH, Golkowski MG, Kenerson HL, Lee KS, Pascual BC, Lim HC, Forbush K, Smith FD, Gordan JD, Ong SE, Yeung RS, Scott JD. Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma. Cell Reports. 43: 113678. PMID 38236773 DOI: 10.1016/j.celrep.2024.113678  0.358
2023 Myint KZ, Sueca-Comes M, Collier P, Balasubramanian B, Venkatraman S, Gordan J, Zaitoun AM, Mukherjee A, Arora A, Larbcharoensub N, Suriyonplengsaeng C, Wongprasert K, Janvilisri T, Gomez D, Grabowska AM, et al. Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma. Frontiers in Oncology. 13: 1184900. PMID 38144528 DOI: 10.3389/fonc.2023.1184900  0.423
2023 Lauer SM, Omar MH, Golkowski MG, Kenerson HL, Pascual BC, Forbush K, Smith FD, Gordan J, Ong SE, Yeung RS, Scott JD. Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma. Biorxiv : the Preprint Server For Biology. PMID 37425703 DOI: 10.1101/2023.06.28.546958  0.381
2023 Chan GKL, Maisel S, Hwang YC, Pascual BC, Wolber RRB, Vu P, Patra KC, Bouhaddou M, Kenerson HL, Lim HC, Long D, Yeung RS, Sethupathy P, Swaney DL, Krogan NJ, ... ... Gordan JD, et al. Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms. Elife. 12. PMID 36692000 DOI: 10.7554/eLife.69521  0.42
2022 Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, Ferrone CR, Deshpande V, Baiev I, Pinto CJ, McLoughlin DE, ... ... Gordan JD, et al. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery. OF1-OF18. PMID 35420673 DOI: 10.1158/2159-8290.CD-21-1168  0.363
2022 Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene. PMID 35087237 DOI: 10.1038/s41388-022-02179-z  0.458
2020 Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, ... ... Gordan JD, et al. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell. PMID 32531271 DOI: 10.1016/J.Ccell.2020.05.003  0.758
2020 El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. The Oncologist. PMID 32400000 DOI: 10.1634/Theoncologist.2020-0367  0.332
2019 Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, et al. Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis. Journal of Hepatology. PMID 31195063 DOI: 10.1016/J.Jhep.2019.05.027  0.393
2019 Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. KRAS inhibition produces a driver-limited state revealing collateral dependencies. Science Signaling. 12. PMID 31138768 DOI: 10.1126/Scisignal.Aaw9450  0.763
2019 Wang P, Song X, Utpatel K, Shang R, Yang YM, Xu M, Zhang J, Che L, Gordan J, Cigliano A, Seki E, Evert M, Calvisi DF, Hu X, Chen X. MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. Cell Death & Disease. 10: 120. PMID 30741922 DOI: 10.1038/S41419-019-1389-4  0.382
2018 Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene. PMID 30390071 DOI: 10.1038/S41388-018-0537-0  0.3
2018 Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, Utpatel K, Ribback S, Pilo MG, Serra M, Gordan JD, Che L, Zhang S, Cossu A, Porcu A, et al. Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30084835 DOI: 10.1158/1078-0432.CCR-18-0284  0.386
2018 Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology. PMID 29942081 DOI: 10.1038/S41589-018-0081-9  0.756
2018 Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. PMID 29545603 DOI: 10.1038/S41388-018-0188-1  0.382
2018 Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, et al. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death & Disease. 9: 31. PMID 29348467 DOI: 10.1038/S41419-017-0183-4  0.314
2018 Kelley RK, Mitchell E, Behr S, Hwang J, Keenan B, Cheung A, Gordan JD, Ko AH, Cinar P, Atreya CE, Van Loon K, Weber T, Ngo Z, Quandt ZE, Liu C, et al. Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). Journal of Clinical Oncology. 36: 386-386. DOI: 10.1200/JCO.2018.36.4_SUPPL.386  0.571
2018 Kelley RK, Mitchell E, Behr S, Hwang J, Keenan B, Umetsu SE, Gordan JD, Ko AH, Cinar P, Atreya CE, Van Loon K, Weber T, Ngo Z, Quandt ZE, Liu C, et al. Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses. Journal of Clinical Oncology. 36: 4087-4087. DOI: 10.1200/JCO.2018.36.15_SUPPL.4087  0.566
2018 Donnella H, Webber J, Shokat K, Goga A, Gordan J, Bandyopadhyay S. Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A45  0.645
2018 Dong M, Liu X, Evert K, Utpatel K, Zhang S, Che L, Gordan J, Calvisi D, evert M, Liu Y, Chen X. Abstract A212: Preclinical efficacy of MEK inhibition in a K-Ras driven cholangiocarcinoma preclinical model Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A212  0.466
2017 Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ. Sampling strategies to capture single-cell heterogeneity. Nature Methods. PMID 28869755 DOI: 10.1038/Nmeth.4427  0.549
2017 Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, ... ... Gordan J, et al. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression. Journal of Hepatology. PMID 28733220 DOI: 10.1016/J.Jhep.2017.07.006  0.389
2016 Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL. An optimized chromatographic strategy for multiplexing in parallel reaction monitoring mass spectrometry: Insights from quantitation of activated kinases. Molecular & Cellular Proteomics : McP. PMID 27940637 DOI: 10.1074/Mcp.M116.058172  0.711
2016 Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, ... Gordan JD, et al. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Molecular Cancer Therapeutics. 15: 1472-84. PMID 27364904 DOI: 10.1158/1535-7163.Mct-15-0554  0.753
2016 Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, et al. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery. 6: 727-39. PMID 27231123 DOI: 10.1158/2159-8290.Cd-15-1442  0.773
2016 Samson S, Zhou AY, Martins M, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan J, Levin R, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemens P, et al. Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities. Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-C88  0.733
2015 Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino Mdel P, Gordan JD, Kakar S, Spitsbergen J, Goga A, Stainier DY. Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish. Plos Genetics. 11: e1005305. PMID 26134322 DOI: 10.1371/Journal.Pgen.1005305  0.327
2015 Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discovery. 5: 154-67. PMID 25501949 DOI: 10.1158/2159-8290.Cd-14-0552  0.756
2015 Kelley RK, Nimeiri HS, Gordan JD, Hwang J, McWhirter RM, Kanakamedala A, Atreya CE, Kulik L, Kircher S, Mulcahy MF, Benson AB, Venook AP. Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 33: TPS501-TPS501. DOI: 10.1200/JCO.2015.33.3_SUPPL.TPS501  0.596
2015 Abou-Alfa GK, Mayer RJ, Cosgrove D, Capanu M, Choti MA, Atreya CE, Ang C, Kelley RK, Do RKG, Gordan JD, Zhu AX, Ly M, Nolan P, Lubin L, Harding JJ, et al. Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC). Journal of Clinical Oncology. 33: e15149-e15149. DOI: 10.1200/Jco.2015.33.15_Suppl.E15149  0.548
2014 Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Reports. 8: 1037-48. PMID 25127139 DOI: 10.1016/J.Celrep.2014.07.010  0.764
2014 Sos ML, Levin R, Gordan J, Oses-Prieto J, Webber J, Salt M, Hann B, Burlingame A, Mccormick F, Bandyopadhyay S, Shokat K. Abstract LB-216: Integrated analysis of differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-216  0.783
2014 Sos M, Levin R, Gordan J, Oses-Prieto J, Webber J, Salt M, Hann B, Burlingame A, McCormick F, Bandyopadhyay S, Shokat K. 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer European Journal of Cancer. 50: 28-29. DOI: 10.1016/S0959-8049(14)70199-6  0.762
Show low-probability matches.